Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MEDI0457 · INO-3112, VGX-3100

Vaccine (DNA plasmid) · Immune activation, directed at HPV 16 E6, HPV 16 E7 and HPV 18 E6 · developed by Inovio Pharmaceuticals

Phase 2 Most advanced trial (none active)

INO Developer

2 Registered trials

What is MEDI0457?

MEDI0457 is a DNA-based vaccine combining VGX-3100 (encoding HPV 16 and 18 E6/E7 antigens) and INO-9012 (encoding IL-12). Delivered by intramuscular injection with electroporation, it elicits cytotoxic T-lymphocyte and natural killer cell responses against HPV-expressing cancer cells. It is studied in cervical cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: INO-3112, VGX-3100, INO-9012, pGX-3002
Drug type: Vaccine (DNA plasmid)
Targets: HPV 16 E6 (antigen), HPV 16 E7 (antigen), HPV 18 E6 (antigen), HPV 18 E7 (antigen)
Mechanism: Immune activation, directed at HPV 16 E6, HPV 16 E7 and HPV 18 E6
Pathways: CTL response, NK cell activation, interferon-gamma secretion
Therapy area: Oncology
Developer: Inovio Pharmaceuticals (INO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: D8W2DVO5ZJ

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02501278	Phase 2	Uterine Cervical Neoplasms	Withdrawn	INO
NCT02172911	Phase 1/2	Cervical Cancer	Completed	INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical CancerUterine Cervical Neoplasms

More from Inovio Pharmaceuticals

DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Phase 1 INO-1400 Phase 1 INO-1401 Phase 1 INO-1800 Phase 1 INO-3106 Phase 1 INO-3107 Phase 1/2 INO-3401 Phase 1 INO-4201 Phase 1 INO-4202 Phase 1 INO-4212 Phase 1 INO-4500 Phase 1 INO-4700 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.

Follow INO, the company behind MEDI0457

See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z